Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction

The quality of evidence regarding patient-centered outcomes in adults with heart failure (HF) after sacubitril combined with valsartan has not been systematically appraised. We searched 4 databases in February 2017 and graded the quality of evidence according to the Grading of Recommendations Assess...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2017-10, Vol.120 (7), p.1166-1170
Hauptverfasser:	Aronow, Wilbert S., Shamliyan, Tatyana A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adults Aminobutyrates - pharmacology Angiotensin Angiotensin Receptor Antagonists - pharmacology Angiotensin-converting enzyme inhibitors Beta blockers Cardiovascular diseases Clinical trials Diabetes Documents Drug Combinations Ejection fraction Emergency medical services Enzyme inhibitors Evaluation Group dynamics Heart Heart diseases Heart failure Heart Failure - drug therapy Heart Failure - physiopathology Humans Morbidity Mortality Patients Peptidyl-dipeptidase A Pharmaceuticals Quality of life Side effects Stroke Volume - drug effects Stroke Volume - physiology Tetrazoles - pharmacology Treatment Outcome Ventricle Ventricular Function, Left - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!